

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/721,341
		Filing Date	November 21, 2000
		First Named Inventor	Gosling, Jennifa et al.
		Art Unit	1647
		Examiner Name	Bunner, Bridget E.
Total Number of Pages in This Submission		Attorney Docket Number	019934-000711US

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input checked="" type="checkbox"/> Petition under 37 CFR 1.47(a) (including Attachments A-D) <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input checked="" type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - Request to Correct Inventorship Under 37 CFR 1.48(a) - Declaration Under 37 CFR 1.48(a) - Declaration Under 37 CFR 1.48(a) - Dale Talbot - Declaration - 3.73(b) Statement - Consent of Assignee for Correction of Inventorship
<input type="checkbox"/> Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Scott L. Ausenhus Reg. No. 42,271
Signature	
Date	November 29, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
Express Mail Label: <u>EV 291376412 US</u>			
I hereby certify that this correspondence is being deposited with the United States Postal Service with "Express Mail Post Office to Address" service under 37 CFR 1.10 on this date November 29, 2004 and is addressed to:			
Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450			
Typed or printed name	Tara N. Damhoff		
Signature		Date	November 29, 2004

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 260

Complete if Known

Application Number	09/721,341
Filing Date	November 21, 2000
First Named Inventor	Gosling, Jennifa
Examiner Name	Bunner, Bridget E.
Art Unit	1647
Attorney Docket No.	019934-000711US

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number

20-1430

Deposit Account Name

Townsend and Townsend and Crew LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1)

(\$0)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims		Fee from below		Fee Paid
Total Claims	<input type="text"/>	-.** =	<input type="text"/>	X	<input type="text"/>	= <input type="text"/>
Independent Claims	<input type="text"/>	-.** =	<input type="text"/>	X	<input type="text"/>	= <input type="text"/>
Multiple Dependent				X	<input type="text"/>	= <input type="text"/>

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$0)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	130
1807	50	1807	50	Petitions related to provisional applications	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) Request to Correct Inventorship


130

*Reduced by Basic Filing Fee Paid SUBTOTAL (3)


(\$260)

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Scott L. Aussenhus	Registration No. (Attorney/Agent)	42,271	Telephone	303-571-4000
Signature				Date	November 29, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



IFW
1647

"Express Mail" Label No. EV 291376412 US
Date of Deposit November 29, 2004

PATENT
Docket No.: 019934-000711US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Mail Stop Issue Fee

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By: _____

Tara N. Damhoff

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jennifa Gosling et al.

Application No.: 09/721,341

Filed: November 21, 2000

For: METHOD FOR IDENTIFYING A
MODULATOR OF THE BINDING
OF CCX CKR POLYPEPTIDE TO
A CHEMOKINE (AMENDED)

Customer No: 20350

Confirmation No.: 5168

Examiner: Bunner, Bridget E.

Art Unit: 1647

COMMUNICATION REGARDING
CHANGE IN INVENTORSHIP

Mail Stop Issue Fee

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper and accompanying documents are filed to correct inventorship in this application, specifically to delete Dale Talbot as a named inventor, who was named as an inventor in error without deceptive intent.

In accordance with the requirements of 37 C.F.R. 1.48(a), the following documents are attached:

(1) Request to Correct Inventorship under 37 C.F.R. 1.48(a);

12/07/2004 GWORDOF1 00000005 201430 09721341

01 FC:1464 130.00 DA

(2) Statement from Dale Talbot stating that it was through error without deceptive intent that he was named as an inventor in the above-identified patent application;

(3) Executed declarations by joint inventors Jennifa Gosling, Daniel J. Dairaghi, Zhenhua Miao and Thomas J. Schall in accordance with 37 C.F.R. §1.63;

(4) Statement Under 37 C.F.R. 3.73(b) signed by Thomas J. Schall on behalf of ChemoCentryx, Inc.;

(5) Written consent from the assignee, ChemoCentryx, Inc., to the change in inventorship; and

(6) Authorization to deduct the request fee of \$130.00, pursuant to 37 C.F.R. §1.17(i), from Deposit Account No. 20-1430 of the undersigned.

Inventor Michael Hanley did not provide an executed declaration listing the correct inventors despite being provided with the documents necessary to effectuate the change in inventorship (i.e., copy of application, currently pending claims and new declaration listing the correct inventors) and being contacted multiple times regarding this matter, thus evidencing a refusal to sign the necessary new declaration. Accordingly, a petition under 37 C.F.R. 1.47(a) is also enclosed to change the inventorship when a joint inventor refuses to join in executing a declaration.

The Patent Office is authorized to charge all fees associated with the request for correction of inventorship and the petition under 37 C.F.R. 1.47(a) to Deposit Account No. 20-1430. Any other fees can also be charged to this Deposit Account.

Jennifa Gosling et al.
Application No.: 09/721,341
Page 3

PATENT


If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at (303) 571-4000.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Scott Ausenhus", written over the printed name.

Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: (303) 571-4000
Fax: (415) 576-0300
SLA:sla
60365459 v1



"Express Mail" Label No. EV 291376412 US
Date of Deposit November 29, 2004

PATENT
Attorney Docket No.: 019934-000711US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Mail Stop Issue Fee

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

By: 

Tara N. Damhoff

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jennifa Gosling et al.

Application No.: 09/721,341

Filed: November 21, 2000

For: METHOD FOR IDENTIFYING A
MODULATOR OF THE
BINDING OF CCX CKR
POLYPEPTIDE TO A
CHEMOKINE (AMENDED)

Customer No.: 20350

Confirmation No.: 5168

Examiner: Bunner, Bridget E.

Art Unit: 1647

REQUEST TO CORRECT
INVENTORSHIP UNDER 37 C.F.R. §
1.48(a)

Mail Stop Issue Fee

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Applicant requests under 37 C.F.R. §1.48(a) to delete Dale Talbot as an inventor to the above-identified patent application.

As required by 37 C.F.R. §1.48(a), the following are submitted herewith:

(1) Statement from Dale Talbot stating that it was through error without deceptive intent that he was named as an inventor in the above-identified patent application;

- (2) Executed declarations by joint inventors Jennifa Gosling, Daniel J. Dairaghi, Zhenhua Miao and Thomas J. Schall in accordance with 37 C.F.R. §1.63;
- (3) Statement Under 37 CFR 3.73(b) signed by Thomas J. Schall on behalf of ChemoCentry, Inc.; and
- (4) Written consent from the assignee, ChemoCentryx, Inc., to the change in Inventorship.

Please deduct the request fee of \$130.00, pursuant to 37 C.F.R. §1.17(i), from Deposit Account No. 20-1430 of the undersigned. Please charge any additional fees or credit overpayment to the above Deposit Account.

Respectfully submitted,



Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 415-576-0300
SLA:tnd
60243207 v1



"Express Mail" Label No. EV 291376412 US

Date of Deposit 11.29.04

PATENT
Attorney Docket No.: 019934-000711US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By: 

Tara N. Damhoff

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jennifa Gosling et al.

Application No.: 09/721,341

Filed: November 21, 2000

For: METHOD FOR IDENTIFYING A
MODULATOR OF THE
BINDING OF CCX CKR
POLYPEPTIDE TO A
CHEMOKINE (AMENDED)

Customer No.: 20350

Customer No.: 5168

Examiner: Bunner, Bridget E.

Art Unit: 1647

DECLARATION UNDER 37 C.F.R. §1.48(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Dale Talbot, state that it was through error without deceptive intent that I was named as an inventor in the above-referenced patent application.

I agree to the correction of inventorship currently requested by the assignees of the above-referenced patent to delete myself, Dale Talbot, as a joint inventor.

Dated: July 14, 2004

By 
Dale Talbot

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 415-576-0300
SLA:tnd

**DECLARATION**

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: METHOD FOR IDENTIFYING A MODULATOR OF THE BINDING OF CCX CKR POLYPEPTIDE TO A CHEMOKINE (AMENDED) the specification of which ____ is attached hereto or X was filed on November 21, 2000 as Application No. 09/721,341 and was amended on August 1, 2001, January 30, 2002, May 28, 2002, November 26, 2002, May 12, 2003 and January 20, 2004.

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date
60/159,015	10/12/99
60/159,210	10/13/99
60/172,979	12/20/99
60/173,388	12/28/99
60/186,626	03/03/00


I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
09/686,020	10/10/00	Pending

Full Name of Inventor 1:	Last Name: GOSLING	First Name: JENNIFA	Middle Name or Initial:	
Residence & Citizenship:	City: San Francisco	State/Foreign Country: California	Country of Citizenship: United States	
Post Office Address:	Post Office Address: 322 Virginia Avenue	City: San Francisco	State/Country: California	Postal Code: 94110




Full Name of Inventor 2:	Last Name: DAIRAGHI	First Name: DANIEL	Middle Name or Initial: J.	
Residence & Citizenship:	City: Palo Alto	State/Foreign Country: California	Country of Citizenship: United States	
Post Office Address:	Post Office Address: 178 El Dorado	City: Palo Alto	State/Country: California	Postal Code: 94306
Full Name of Inventor 3:	Last Name: HANLEY	First Name: MICHAEL	Middle Name or Initial:	
Residence & Citizenship:	City: Corte Madera	State/Foreign Country: California	Country of Citizenship: United States	
Post Office Address:	Post Office Address: 81 Parkview Circle	City: Corte Madera	State/Country: California	Postal Code: 94925
Full Name of Inventor 4:	Last Name: MIAO	First Name: ZHENHUA	Middle Name or Initial:	
Residence & Citizenship:	City: San Jose	State/Foreign Country: California	Country of Citizenship: Peoples Republic of China	
Post Office Address:	Post Office Address: 7070 Rainbow Drive, #2	City: San Jose	State/Country: California	Postal Code: 95129
Full Name of Inventor 5:	Last Name: SCHALL	First Name: THOMAS	Middle Name or Initial: J.	
Residence & Citizenship:	City: Palo Alto	State/Foreign Country: California	Country of Citizenship: United States	
Post Office Address:	Post Office Address: 563 Homer Ave.	City: Palo Alto	State/Country: California	Postal Code: 94301


I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1  Jennifa Gosling Date <u>6.28.2004</u>	Signature of Inventor 2 _____ Daniel J. Dairaghi Date _____	Signature of Inventor 3 _____ Michael Hanley Date _____
Signature of Inventor 4 _____ Zhenhua Miao Date _____	Signature of Inventor 5 _____ Thomas J. Schall Date _____	

Full Name of Inventor 2:	Last Name: DAIRAGHI	First Name: DANIEL	Middle Name or Initial: J.	
Residence & Citizenship:	City: Palo Alto	State/Foreign Country: California	Country of Citizenship: United States	
Post Office Address:	Post Office Address: 178 El Dorado	City: Palo Alto	State/Country: California	Postal Code: 94306
Full Name of Inventor 3:	Last Name: HANLEY	First Name: MICHAEL	Middle Name or Initial:	
Residence & Citizenship:	City: Corte Madera	State/Foreign Country: California	Country of Citizenship: United States	
Post Office Address:	Post Office Address: 81 Parkview Circle	City: Corte Madera	State/Country: California	Postal Code: 94925
Full Name of Inventor 4:	Last Name: MIAO	First Name: ZHENHUA	Middle Name or Initial:	
Residence & Citizenship:	City: San Jose	State/Foreign Country: California	Country of Citizenship: Peoples Republic of China	
Post Office Address:	Post Office Address: 7070 Rainbow Drive, #2	City: San Jose	State/Country: California	Postal Code: 95129
Full Name of Inventor 5:	Last Name: SCHALL	First Name: THOMAS	Middle Name or Initial: J.	
Residence & Citizenship:	City: Palo Alto	State/Foreign Country: California	Country of Citizenship: United States	
Post Office Address:	Post Office Address: 563 Homer Ave.	City: Palo Alto	State/Country: California	Postal Code: 94301

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1 Jennifa Gosling Date _____	Signature of Inventor 2  Daniel J. Dairaghi Date <u>23 June 2004</u>	Signature of Inventor 3 Michael Hanley Date _____
Signature of Inventor 4  Zhenhua Miao Date <u>6/29/04</u>	Signature of Inventor 5  Thomas J. Schall Date <u>7/2/04</u>	



"Express Mail" Label No. EV 291376412 US
Date of Deposit 11-29-04

PATENT
Attorney Docket No.: 019934-000711US

I hereby certify that this is being deposited with the United States Postal
Service "Express Mail Post Office to Address" service under 37 CFR 1.10
on the date indicated above and is addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By: Tara N. Damhoff

Tara N. Damhoff

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jennifa Gosling et al.

Application No.: 09/721,341

Filed: November 21, 2000

For: METHOD FOR IDENTIFYING A
MODULATOR OF THE
BINDING OF CCX CKR
POLYPEPTIDE TO A
CHEMOKINE (AMENDED)

Customer No.: 20350

Customer No.: 5168

Examiner: Bunner, Bridget E.

Art Unit: 1647

CONSENT OF ASSIGNEE FOR
CORRECTION OF INVENTORSHIP
UNDER 37 C.F.R. § 1.48(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The assignee of the above-identified patent application, ChemoCentryx, Inc., consents to
amending the subject application to delete Dale Talbot as an inventor.

In accordance with 37 C.F.R. §3.73(b), a certificate of assignment is enclosed to establish
ownership of the above-identified application by ChemoCentryx, Inc.

CHEMOCENTRYX, INC.

Date 6/30/04

By: Thomas J. Schall

Name: Thomas J. Schall
Title: President and CEO

**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant/Patent Owner: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, Thomas J. Schall
(applicants as corrected)

Application No./Patent No.: 09/721,341Filed/Issue Date: November 21, 2000Entitled: METHOD FOR IDENTIFYING A MODULATOR OF THE BINDING OF CCX CKR POLYPEPTIDE TO A CHEMOKINE (AMENDED)ChemoCentryx, Inc., a Delaware corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____%

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 011909, Frame 0816, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To : _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To : _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To : _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

6/30/04
Date

650-632-2900

Telephone number

Thomas J. Schall

Typed or printed name

[Signature]
Signature

President and Chief Executive Officer

Title



"Express Mail" Label No. EV 291376412 US

Date of Deposit November 29, 2004

PATENT
Docket No.: 019934-000711US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Mail Stop Issue Fee

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

By: _____


Tara N. Damhoff

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jennifa Gosling et al.

Application No.: 09/721,341

Filed: November 21, 2000

For: METHOD FOR IDENTIFYING A
MODULATOR OF THE BINDING
OF CCX CKR POLYPEPTIDE TO
A CHEMOKINE (AMENDED)

Customer No.: 20350

Confirmation No.: 5168

Examiner: Bunner, Bridget E.

Art Unit: 1647

PETITION UNDER 37 C.F.R. 1.47(a)

Mail Stop Issue Fee

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 C.F.R. 1.47(a), Applicants hereby petition for entry of the new declaration that is enclosed. This new declaration is provided as part of a request for correction of inventorship under 37 C.F.R. 1.48(a). As indicated in the enclosed request, Applicants are petitioning for deletion of Dale Talbot as a named inventor. Inventor Michael Hanley, however, has refused to sign the new declaration that is required under 37 C.F.R. 1.48(a), despite multiple attempts to contact Mr. Hanley. In

this regard, Applicants note that the deleted inventor, Dale Talbot, has executed the necessary documents to effectuate the change in inventorship.

Statement of Facts

As required for a petition under 37 C.F.R. 1.47(a), the undersigned provides the following statement of facts evidencing a refusal by Michael Hanley to sign the new declaration:

(1) On June 22, 2004, a letter (Attachment A) was sent to Mr. Hanley at his business address (see below) by FedEx requesting that he sign a new declaration to remove Dale Talbot as inventor. The letter enclosed a copy of the application (referred to in the letter as the 019934-000710 application), a copy of the claims as currently pending, and a copy of the new declaration for signature by Mr. Hanley. A copy of a FedEx delivery receipt (Attachment B) is enclosed, confirming delivery of the materials to Mr. Hanley's place of employment on June 23, 2004.

(2) On July 15, 2004, after not receiving the executed declaration, the undersigned's secretary tried contacting Mr. Hanley and spoke with Mr. Hanley's secretary. Mr. Hanley's secretary confirmed that Mr. Hanley had received the materials and stated that Mr. Hanley considered this matter a low priority and would attend to it when he had time.

(3) On August 11, 2004, the undersigned sent another letter (Attachment C) to Mr. Hanley at his business address reminding Mr. Hanley of the need for the new declaration and noting that the necessary documents from all the other inventors had been received. A copy of a FedEx delivery receipt (Attachment D) is enclosed, confirming delivery of the materials to Mr. Hanley's place of employment on August 12, 2004.

(4) On October 19, 2004, the undersigned tried calling Mr. Hanley and reached his secretary, Rosemary, who said that she would leave a message with Mr. Hanley to contact the undersigned to discuss this patent matter.

(5) On October 20, 2004, the undersigned called Mr. Hanley and again reached his secretary, Rosemary. Mr. Hanley's secretary confirmed that she had relayed the undersigned's previous message to Mr. Hanley and said she would again remind Mr. Hanley to contact the undersigned.

(6) After not hearing from Mr. Hanley, the undersigned again called Mr. Hanley on October 26, 2004 and this time reached Mr. Hanley's personal voicemail rather than Mr. Hanley's secretary. The undersigned left a message requesting Mr. Hanley to call about changing inventorship in this application and noting that all the other inventors had signed the necessary documents. Mr. Hanley never returned the undersigned's calls.

Applicants submit that this chronology of events clearly demonstrate that Mr. Hanley was provided with the necessary documents (including application, currently pending claims and new declaration) to correct inventorship in this application and his refusal to execute the necessary declaration. Applicants thus request that this petition under 37 C.F.R. 1.47(a) be granted and that the enclosed new declaration signed by all the other correct inventors be entered into the file as part of the enclosed request to correct inventorship (i.e., to delete Dale Talbot as inventor, thus leaving Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao and Thomas J. Schall as the correct inventors).

Last Known Address

Applicants are only aware of Mr. Hanley's current business address, which is Amylin Pharmaceuticals, Inc., 9360 Towne Center Drive, Ste. 110, San Diego, CA 92121.

Petition Fee

The Patent Office is authorized to charge the petition fee under 37 C.F.R. 1.17(h) to Deposit Account No. 20-1430, as well as any other fee that may be due as part of the processing of this petition.

Jennifa Gosling et al.
Application No.: 09/721,341
Page 4

PATENT

If this petition is more properly brought under 37 C.F.R. 1.183, then Applicants request that this petition be treated as such and that the necessary fees for such a petition be charged to Deposit Account No. 20-1430, as well as any other fee that may be due as part of the processing of this petition.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at (303)571-4000.


Respectfully submitted,

A handwritten signature in black ink, appearing to read "Scott Ausenhus", written over the typed name.

Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: (303)571-4000
Fax: (415) 576-0300
SLA:sla

TOWNSEND
and
TOWNSEND
and
CREW
LLP



San Francisco, California
Tel 415 576-0200

Palo Alto, California
Tel 650 326-2400

Walnut Creek, California
Tel 925 472-5000

San Diego, California
Tel 858-350-6100

Seattle, Washington
Tel 206 467-9600

Denver

1200 Seventeenth Street
Suite 2700
Denver
Colorado 80202-5827
Tel 303 571-4000
Fax 303 571-4321

June 22, 2004

VIA FEDEX

Michael Hanley, Ph.D.
Vice President Discovery Research
Amylin Pharmaceuticals, Inc.
9360 Towne Centre Drive, Ste. 110
San Diego, CA 92121

Re: ChemoCentryx Patent Applications
Our File No.: 019934-000710US
Our File No.: 019934-000711US
Our File No.: 019934-000723US

Dear Dr. Hanley:

I am a patent attorney and am currently assisting ChemoCentryx, Inc. with the above-referenced patent applications.

ChemoCentryx has undertaken a review of the inventors listed in these applications to evaluate whether inventorship needs to be altered in view of the pending claims. It was determined that inventorship should be altered in these applications as indicated below:

Our Files 019934-000711US and -000723US: Remove Dale Talbot as inventor;

Our File 019934-000710US: Remove Dale Talbot and yourself as inventors.

A copy of the 019934-000710US and -000723US applications as filed and the claims as currently pending in each application are also enclosed for your reference (the 019934-000711US application is identical to the -000710US application and thus is not included). These documents are of course confidential and should not be disclosed to anyone else.

After reviewing the applications and claims, please sign and DATE the enclosed documents and return them and the enclosures to me as soon as possible in the Federal Express envelope that is enclosed for your convenience. The documents that are enclosed include:

Our Files 019934-000711US and -000723US: A new declaration listing the correct inventors. This declaration should be signed and DATED by you in the spaces provided. The other inventors will sign other copies of the declaration.

Our File 019934-000710US: A statement by you requesting a change of inventorship.

ChemoCentryx appreciates your assistance in this matter. Please do not hesitate to contact me if you have any questions or concerns regarding this matter.

Very truly yours,



Scott L. Ausenhus

SLA/tnd

Enclosures

cc: Mark Penfold, ChemoCentryx, Inc. (*Via Federal Express*, w/o Enclosures)
60245259 v1

Damhoff, Tara N.

From: FedEx [donotreply@fedex.com]
Sent: Wednesday, June 23, 2004 11:14 AM
To: Damhoff, Tara N.
Subject: FedEx shipment 790677235553

Our records indicate that the shipment sent from Scott Ausenhus/Townsend & Townsend & Cre to Michael Hanley, Ph.D./Amylin Pharmaceuti has been delivered. The package was delivered on 06/23/2004 at 9:39 AM and signed for or released by E.MOLINA.

The ship date of the shipment was 06/22/2004.

The tracking number of this shipment was 790677235553.

FedEx appreciates your business. For more information about FedEx services, please visit our web site at <http://www.fedex.com>

To track the status of this shipment online please use the following:
[http://www.fedex.com/cgi-bin/tracking?tracknumbers=790677235553
&action=track&language=english&cntry_code=us](http://www.fedex.com/cgi-bin/tracking?tracknumbers=790677235553&action=track&language=english&cntry_code=us)

Disclaimer

FedEx has not validated the authenticity of any email address.

TOWNSEND
and
TOWNSEND
and
CREW
LLP

San Francisco, California
Tel 415 576-0200

Palo Alto, California
Tel 650 326-2400

Walnut Creek, California
Tel 925 472-5000

San Diego, California
Tel 858-350-6100

Seattle, Washington
Tel 206 467-9600

Denver

1200 Seventeenth Street
Suite 2700
Denver
Colorado 80202-5827
Tel 303 571-4000
Fax 303 571-4321

August 11, 2004

VIA FEDEX

Michael Hanley, Ph.D.
Vice President Discovery Research
Amylin Pharmaceuticals, Inc.
9360 Towne Centre Drive, Ste. 110
San Diego, CA 92121

Re: ChemoCentryx Patent Applications
Our File No.: 019934-000710US
Our File No.: 019934-000711US
Our File No.: 019934-000723US

Dear Dr. Hanley:

As I indicated in my earlier letter to you dated June 22, 2004, ChemoCentryx Inc. is requesting your cooperation in correcting the inventorship in these three applications. We have received the necessary papers from all the other inventors, and are now just awaiting the papers from you.


To elaborate somewhat on my earlier letter, and as you can see from the applications and claims I provided you previously, the subject matter of the foregoing applications falls into two categories:

1. The 019934-000711US and -000723US applications, which are directed to screening methods to identify agents that modulate the activity of the chemokine receptor CCX CKR. ChemoCentryx has concluded that you are an inventor of the claims in these applications and thus simply needs you to sign the papers I provided you for these applications to have Mr. Dale Talbot removed as a named inventor. Mr. Talbot has already agreed to this change and sent us the necessary formal documents he needed to sign to effectuate this change.
2. The 019934-000710US application, which is directed to methods of treating a CCX CKR medicated condition in a mammal. ChemoCentryx has concluded that the work underlying this invention was performed by others after your departure from ChemoCentryx. The papers I provided you with previously thus are to remove Mr. Talbot and yourself as named inventors. Again, Mr. Talbot has already signed the appropriate papers.

If you have any questions or concerns about this matter or need another copy of the applications and claims that were sent with my letter dated June 22, 2004, please do not hesitate to contact me. Upon receipt of the documents from you we can conclude this matter.

Once again, ChemoCentryx would like to thank you in advance for your cooperation in this matter.

Very truly yours,



Scott L. Ausenhus

SLA/tnd

cc: Mark Penfold, ChemoCentryx, Inc. (*Via U.S. Mail*)
60245259 v1

Damhoff, Tara N.

From: FedEx [donotreply@fedex.com]
Sent: Thursday, August 12, 2004 12:55 PM
To: Damhoff, Tara N.
Subject: FedEx shipment 790729963781

Our records indicate that the shipment sent from Scott Ausenhus/Townsend & Townsend & Cre to Michael Hanley, Ph.D./Amylin Pharmaceuti has been delivered. The package was delivered on 08/12/2004 at 9:42 AM and signed for or released by E.MOLINA.

The ship date of the shipment was 08/11/2004.

The tracking number of this shipment was 790729963781.

FedEx appreciates your business. For more information about FedEx services, please visit our web site at <http://www.fedex.com>

To track the status of this shipment online please use the following:
[http://www.fedex.com/cgi-bin/tracking?tracknumbers=790729963781
&action=track&language=english&cntry_code=us](http://www.fedex.com/cgi-bin/tracking?tracknumbers=790729963781&action=track&language=english&cntry_code=us)

Disclaimer

FedEx has not validated the authenticity of any email address.